Cancer Vaccine Market
Cancer Vaccine Market Size, Share & Trends Analysis Report by Type (Preventive Vaccines, and Therapeutic Vaccines) by Technology (Dendritic Cell Vaccines, Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, and Recombinant Vector Vaccines) and by End-User (Hospitals and Clinics, Research Institutes, Pharmaceuticals & Biotechnology Companies, and Others) Forecast Period (2025-2035)
Industry Overview
Cancer vaccine market was valued at $11.20 billion in 2024 and is projected to reach $36.14 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2025–2035). The market growth in cancer therapies is driven by several factors, such as the rising prevalence of cancer globally, advancements in immunotherapy and mRNA technologies, increased investment in R&D by pharmaceutical companies, and a shift towards personalized medicine tailored to individual patient needs. Additionally, growing patient awareness and supportive regulatory frameworks, such as the FDA's breakthrough therapy designation, further promote market expansion.
Market Dynamics
Rising Cancer Incidence
The increasing prevalence of cancer worldwide is a major driver for the growth of the cancer vaccine market. According to the World Health Organization, cancer is a leading cause of death globally, with an estimated 20 million new cases and 9.7 million deaths in 2022
Advancements in Immunotherapy
Recent developments in immunotherapy, particularly in personalized and neoantigen-based vaccines, are propelling the market forward. These therapies aim to stimulate the immune system to target and destroy cancer cells more effectively.
Supportive Government Initiatives
Governments worldwide are implementing national immunization programs to combat cancer. For instance, Pakistan has vaccinated approximately 9 million girls against the human papillomavirus (HPV), aiming to reduce cervical cancer incidence.
Market Segmentation
- Based on the type, the market is segmented into preventive vaccines and therapeutic vaccines.
- Based on the technology, the market is segmented into dendritic cell vaccines, conjugate vaccines, inactivated vaccines, live attenuated vaccines, and recombinant vector vaccines.
- Based on the end user, the market is segmented into hospitals and clinics, research institutes, pharmaceuticals & biotechnology companies, and others.
Preventive Vaccines Largest Segment in the Global Cancer Vaccine Market
The preventive vaccines segment holds the largest share in the global cancer vaccine market. This includes vaccines such as the HPV and Hepatitis B vaccines, which are widely used to prevent cancers like cervical and liver cancer. The success of these vaccines in reducing cancer incidence has led to their widespread adoption and significant market share.
Regional Outlook
The global cancer vaccine market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Maintains Strong Market Position
In North America, the US dominates the global cancer vaccine Market with a major share, driven by its advanced healthcare infrastructure, strong biotechnology and pharmaceutical presence, and significant investments in oncology research and immunotherapy development. The country’s leadership is largely attributed to its robust R&D ecosystem supported by both government and private sector funding through organizations such as the National Cancer Institute (NCI) and the National Institutes of Health (NIH), which continuously promote innovation in preventive and therapeutic cancer vaccines. Additionally, the presence of major biotechnology companies such as Moderna, Gilead Sciences, Bristol Myers Squibb, and Merck & Co., which have pioneered groundbreaking immuno-oncology products like the HPV vaccine Gardasil and mRNA-based vaccine technologies, strengthens the US position in this market.
High cancer prevalence and growing demand for personalized treatment approaches have also accelerated the adoption of cancer vaccines for both prevention and therapy. Favorable regulatory policies by the US Food and Drug Administration (FDA), along with faster approval processes for breakthrough therapies, have encouraged continuous clinical trials and the commercialization of new vaccine candidates. Moreover, increasing collaborations between academic institutions and biopharma companies for next-generation vaccines, coupled with rising awareness about immunization and early cancer detection, continue to fuel market growth. As a result, the US maintains its dominant role in setting global benchmarks for innovation, clinical advancement, and commercialization within the cancer vaccine landscape.
Market Players Outlook
The major companies operating in the global cancer vaccine market include GlaxoSmithKline plc (GSK), Merck & Co., Inc., Moderna, Inc., Pfizer, Inc., Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2025, BioNTech announced plans to invest up to £1 billion ($1.33 billion) in the United Kingdom over the next decade to expand its research and development activities, including personalized cancer therapies.
- In September 2025, Bristol Myers Squibb entered into an $11 billion partnership with BioNTech to co-develop and commercialize a promising cancer drug, BNT327, which shows potential to outperform existing therapies.
- In September 2025, Enteromix, a personalized mRNA-based cancer vaccine developed in Russia, showed 100% efficacy and safety in clinical trials. It trains the immune system to target and eliminate cancer cells without serious side effects, utilizing similar technology to that of COVID-19 vaccines. The vaccine is currently awaiting final approval from the Ministry of Health for public use.
- In September 2025, Pakistan successfully vaccinated approximately 9 million girls against HPV, aiming to reduce cervical cancer incidence, despite challenges posed by misinformation.
The Report Covers
- Market value data analysis of 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cancer vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Cancer Vaccine Market Sales Analysis – Type| Technology | End-User ($ Million)
- Cancer Vaccine Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Cancer Vaccine Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global Cancer Vaccine Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Cancer Vaccine Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Cancer Vaccine Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Cancer Vaccine Market Revenue and Share by Manufacturers
- Cancer Vaccine Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- GlaxoSmithKline plc (GSK)
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Moderna, Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Pfizer, Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Sanofi S.A
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline plc (GSK)
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Global Cancer Vaccine Market Sales Analysis By Type ($ Million)
- Preventive Vaccines
- Therapeutic vaccines
- Global Cancer Vaccine Market Sales Analysis By Technology ($ Million)
- Dendritic Cell Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Live Attenuated Vaccines
- Recombinant Vector Vaccines
- Global Cancer Vaccine Market Sales Analysis By End-User ($ Million)
- Hospitals and Clinics
- Research Institutes
- Pharmaceuticals & Biotechnology Companies
- Others
- Regional Analysis
- North American Cancer Vaccine Market Sales Analysis – Type| Technology | End-User ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Cancer Vaccine Market Sales Analysis – Type| Technology | End-User ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Cancer Vaccine Market Sales Analysis – Type| Technology | End-User ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Cancer Vaccine Market Sales Analysis – Type| Technology | End-User ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Antigenics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Avax Technologies
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BioNTech
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CureVac
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Dendreon Pharmaceuticals LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Immatics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Inovio Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- JW CreaGene
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Moderna Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Northwest Biotherapeutics
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- OncoTherapy Science
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Replimune Group
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Serum Institute of India Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai Zerun Biotechnology Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vaccinogen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Verity Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Wantai BioPharm
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Antigenics
1. Global Cancer Vaccine Market Research and Analysis By Type, 2024-2035 ($ Million)
2. Global Preventive Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
3. Global Therapeutic Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
4. Global Cancer Vaccine Market Research and Analysis By Technology, 2024-2035 ($ Million)
5. Global Dendritic Cell In Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
6. Global Conjugate In Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
7. Global Inactivated Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
8. Global Live Attenuated In Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
9. Global Recombinant Vector In Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
10. Global Cancer Vaccine Market Research and Analysis By End-User, 2024-2035 ($ Million)
11. Global Cancer Vaccine For Hospitals and Clinics Market Research and Analysis By Region, 2024-2035 ($ Million)
12. Global Cancer Vaccine For Research Institutes Market Research and Analysis By Region, 2024-2035 ($ Million)
13. Global Cancer Vaccine For Pharmaceuticals & Biotechnology Companies Market Research and Analysis By Region, 2024-2035 ($ Million)
14. Global Cancer Vaccine For Other End User Market Research and Analysis By Region, 2024-2035 ($ Million)
15. Global Cancer Vaccine Market Research and Analysis By Region, 2024-2035 ($ Million)
16. North American Cancer Vaccine Market Research and Analysis By Country, 2024-2035 ($ Million)
17. North American Cancer Vaccine Market Research and Analysis By Type, 2024-2035 ($ Million)
18. North American Cancer Vaccine Market Research and Analysis By Technology, 2024-2035 ($ Million)
19. North American Cancer Vaccine Market Research and Analysis By End-User, 2024-2035 ($ Million)
20. European Cancer Vaccine Market Research and Analysis By Country, 2024-2035 ($ Million)
21. European Cancer Vaccine Market Research and Analysis By Type, 2024-2035 ($ Million)
22. European Cancer Vaccine Market Research and Analysis By Technology, 2024-2035 ($ Million)
23. European Cancer Vaccine Market Research and Analysis By End-User, 2024-2035 ($ Million)
24. Asia-Pacific Cancer Vaccine Market Research and Analysis By Country, 2024-2035 ($ Million)
25. Asia-Pacific Cancer Vaccine Market Research and Analysis By Type, 2024-2035 ($ Million)
26. Asia-Pacific Cancer Vaccine Market Research and Analysis By Technology, 2024-2035 ($ Million)
27. Asia-Pacific Cancer Vaccine Market Research and Analysis By End-User, 2024-2035 ($ Million)
28. Rest Of The World Cancer Vaccine Market Research and Analysis By Country, 2024-2035 ($ Million)
29. Rest Of The World Cancer Vaccine Market Research and Analysis By Type, 2024-2035 ($ Million)
30. Rest Of The World Cancer Vaccine Market Research and Analysis By Technology, 2024-2035 ($ Million)
31. Rest Of The World Cancer Vaccine Market Research and Analysis By End-User, 2024-2035 ($ Million)
1. Global Cancer Vaccine Market Share By Type, 2024 Vs 2035 (%)
2. Global Preventive Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
3. Global Therapeutic Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
4. Global Cancer Vaccine Market Share By Technology, 2024 Vs 2035 (%)
5. Global Dendritic Cell In Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
6. Global Conjugate In Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
7. Global Inactivated Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
8. Global Live Attenuated In Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
9. Global Recombinant Vector In Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
10. Global Cancer Vaccine Market Share By End-User, 2024 Vs 2035 (%)
11. Global Cancer Vaccine For Hospitals and Clinics Market Share By Region, 2024 Vs 2035 (%)
12. Global Cancer Vaccine For Research Institutes Market Share By Region, 2024 Vs 2035 (%)
13. Global Cancer Vaccine For Pharmaceuticals & Biotechnology Companies Market Share By Region, 2024 Vs 2035 (%)
14. Global Cancer Vaccine For Other End User Market Share By Region, 2024 Vs 2035 (%)
15. Global Cancer Vaccine Market Share By Region, 2024 Vs 2035 (%)
16. US Cancer Vaccine Market Size, 2024-2035 ($ Million)
17. Canada Cancer Vaccine Market Size, 2024-2035 ($ Million)
18. UK Cancer Vaccine Market Size, 2024-2035 ($ Million)
19. France Cancer Vaccine Market Size, 2024-2035 ($ Million)
20. Germany Cancer Vaccine Market Size, 2024-2035 ($ Million)
21. Italy Cancer Vaccine Market Size, 2024-2035 ($ Million)
22. Spain Cancer Vaccine Market Size, 2024-2035 ($ Million)
23. Russia Cancer Vaccine Market Size, 2024-2035 ($ Million)
24. Rest of Europe Cancer Vaccine Market Size, 2024-2035 ($ Million)
25. India Cancer Vaccine Market Size, 2024-2035 ($ Million)
26. China Cancer Vaccine Market Size, 2024-2035 ($ Million)
27. Japan Cancer Vaccine Market Size, 2024-2035 ($ Million)
28. South Korea Cancer Vaccine Market Size, 2024-2035 ($ Million)
29. Australia and New Zealand Cancer Vaccine Market Size, 2024-2035 ($ Million)
30. ASEAN Economies Cancer Vaccine Market Size, 2024-2035 ($ Million)
31. Rest of Asia-Pacific Cancer Vaccine Market Size, 2024-2035 ($ Million)
32. Latin America Cancer Vaccine Market Size, 2024-2035 ($ Million)
33. Middle East and Africa Cancer Vaccine Market Size, 2024-2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Cancer Vaccine Market in 2024 is estimated to be around $11.20B.
North America holds the largest share in the Cancer Vaccine Market.
Leading players in the Cancer Vaccine Market include GlaxoSmithKline plc (GSK), Merck & Co., Inc., Moderna, Inc., Pfizer, Inc., Sanofi S.A., among others.
Cancer Vaccine Market is expected to grow at a CAGR of 11.3% from 2025 to 2035.
Rising cancer prevalence, advancements in immunotherapy, and increasing R&D investments in preventive and therapeutic vaccines are driving the growth of the cancer vaccine market.
